JP2018525358A - アピリモドを用いる癌の処置方法 - Google Patents

アピリモドを用いる癌の処置方法 Download PDF

Info

Publication number
JP2018525358A
JP2018525358A JP2018502669A JP2018502669A JP2018525358A JP 2018525358 A JP2018525358 A JP 2018525358A JP 2018502669 A JP2018502669 A JP 2018502669A JP 2018502669 A JP2018502669 A JP 2018502669A JP 2018525358 A JP2018525358 A JP 2018525358A
Authority
JP
Japan
Prior art keywords
apilimod
cancer
composition
lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018502669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525358A5 (enExample
Inventor
リチェンステイン，ヘンリ
ロスバーグ，ジョナサン・エム
ゲイル，ソフィア
ビーハリー，ニール
ベケット，ポール
ランドレット，ショーン
コンラッド，クリス
シュイ，ティエン
Original Assignee
ラム・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラム・セラピューティクス，インコーポレーテッド filed Critical ラム・セラピューティクス，インコーポレーテッド
Publication of JP2018525358A publication Critical patent/JP2018525358A/ja
Publication of JP2018525358A5 publication Critical patent/JP2018525358A5/ja
Priority to JP2021084241A priority Critical patent/JP2021121611A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018502669A 2015-07-20 2016-07-19 アピリモドを用いる癌の処置方法 Pending JP2018525358A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021084241A JP2021121611A (ja) 2015-07-20 2021-05-19 アピリモドを用いる癌の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562194367P 2015-07-20 2015-07-20
US62/194,367 2015-07-20
PCT/US2016/042905 WO2017015262A1 (en) 2015-07-20 2016-07-19 Methods for treating cancer using apilimod

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021084241A Division JP2021121611A (ja) 2015-07-20 2021-05-19 アピリモドを用いる癌の処置方法

Publications (2)

Publication Number Publication Date
JP2018525358A true JP2018525358A (ja) 2018-09-06
JP2018525358A5 JP2018525358A5 (enExample) 2019-08-29

Family

ID=56551023

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018502669A Pending JP2018525358A (ja) 2015-07-20 2016-07-19 アピリモドを用いる癌の処置方法
JP2021084241A Withdrawn JP2021121611A (ja) 2015-07-20 2021-05-19 アピリモドを用いる癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021084241A Withdrawn JP2021121611A (ja) 2015-07-20 2021-05-19 アピリモドを用いる癌の処置方法

Country Status (13)

Country Link
US (1) US10350213B2 (enExample)
EP (1) EP3325014B1 (enExample)
JP (2) JP2018525358A (enExample)
KR (1) KR20180030630A (enExample)
CN (1) CN108025076A (enExample)
AU (1) AU2016297555B2 (enExample)
BR (1) BR112018000776A2 (enExample)
CA (1) CA2991779A1 (enExample)
IL (1) IL256836B (enExample)
MX (1) MX2018000715A (enExample)
RU (1) RU2738934C2 (enExample)
TW (1) TWI746449B (enExample)
WO (1) WO2017015262A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
CN107249638B (zh) 2014-11-07 2021-05-14 人工智能治疗公司 阿匹莫德用于治疗肾癌
ES2734081T3 (es) * 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
JP2019502707A (ja) * 2016-01-21 2019-01-31 ラム・セラピューティクス，インコーポレーテッド 癌をアピリモドで処置するためのバイオマーカー
CN111565716B (zh) 2017-09-08 2023-06-09 因斯格尼斯疗法有限公司 使用地匹福林的方法
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2022094058A1 (en) * 2020-10-28 2022-05-05 The Regents Of The University Of Michigan Methods for preventing or treating conditions related to pikfyve activity
BR112023025552A2 (pt) * 2021-06-11 2024-02-27 Orphai Therapeutics Inc Composições estabilizadas de apilimod e usos das mesmas
EP4444310A4 (en) * 2021-12-10 2025-11-19 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025175564A1 (en) * 2024-02-23 2025-08-28 The Regents Of The University Of Michigan Method for treating autophagy dependent cancer with a pikfyve degrader

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015095410A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
CU23475A1 (es) * 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
CA3120505C (en) * 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
AU2014244518A1 (en) * 2013-03-14 2015-09-17 Pharmacyclics Llc Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
AU2015209133B2 (en) * 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2015095410A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY & BIOLOGY, vol. 20, JPN6020017506, 2013, pages 912 - 921, ISSN: 0004604885 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 33, JPN6020017505, 2013, pages 4199 - 4206, ISSN: 0004604884 *

Also Published As

Publication number Publication date
CN108025076A (zh) 2018-05-11
TW201717957A (zh) 2017-06-01
RU2018105923A3 (enExample) 2019-12-20
BR112018000776A2 (pt) 2018-09-04
HK1254258A1 (zh) 2019-07-12
US20170020884A1 (en) 2017-01-26
EP3325014B1 (en) 2021-05-19
AU2016297555A1 (en) 2018-03-01
RU2738934C2 (ru) 2020-12-18
IL256836A (en) 2018-03-29
EP3325014A1 (en) 2018-05-30
JP2021121611A (ja) 2021-08-26
AU2016297555B2 (en) 2021-08-19
IL256836B (en) 2021-04-29
KR20180030630A (ko) 2018-03-23
MX2018000715A (es) 2018-06-06
TWI746449B (zh) 2021-11-21
CA2991779A1 (en) 2017-01-26
WO2017015262A1 (en) 2017-01-26
US10350213B2 (en) 2019-07-16
RU2018105923A (ru) 2019-08-20

Similar Documents

Publication Publication Date Title
US11266654B2 (en) Apilimod compositions and methods for using same
JP2021121611A (ja) アピリモドを用いる癌の処置方法
AU2015342876B2 (en) Apilimod for use in the treatment of colorectal cancer
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
JP2016520662A (ja) Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ
HK1254258B (en) Methods for treating cancer using apilimod
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211001